Brought to you by 
Ambit completes $60.5mm IPO
17 May 2013
Executive Summary
Ambit Biosciences Corp. (developing kinase inhibitors) has finally completed its initial public offering, netting $60.5mm through the sale of 8mm shares at $8. The company first filed in November 2010 but withdrew in June 2011, and then filed again in February 2013. Earlier this month, Ambit announced that it hoped to sell 4.6mm shares for between $13-15 apiece.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ambit completes $60.5mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice